Facebook
Twitter
LinkedIn
ForwardSNO Molecular Pathology FAST Series Webinar: Pyrimidine synthesis in IDH-mutant glioma: Identification of BAY 2402234 as a novel therapeutic strategy
Molecular Pathology Special Interest Track Quarterly Series: Tuesday February 21, 2023, at 1:00 pm ET- 2:00 pm ET
Pyrimidine synthesis in IDH-mutant glioma: Identification of BAY 2402234 as a novel therapeutic strategy
Complimentary Registration!
Please email olivia@soc-neuro-onc.org for technical issues.
Target Audience
Neuro-Oncologists, Neuropathologists, Neurosurgeons, and Basic and Translational researchers studying brain tumors
Learning Objectives
- Gain knowledge of the de novo pyrimidine synthesis pathway and its role as a therapeutic target in IDH-mutant glioma.
- Understand evidence validating efficacy of the de novo pyrimidine synthesis inhibitor BAY 2402234 in grade 3 and 4 IDH-mutant astrocytomas.
- Develop an understanding of the mechanisms by which IDH mutations sensitize gliomas to BAY 2402234.
| Speaker | Principal Investigator | Moderator |
|---|---|---|
| Diana Shi | Samuel McBrayer | Julie Miller |
| Dana-Farber Cancer Institute | UT Southwestern | Massachusetts General Hospital |
Molecular Pathology Special Interest Track Chairs:
| Stephen Yip | Sandro Santagata | Jason Huse |
| Vancouver General Hospital | Harvard Medical School | MD Anderson Cancer Center |
SNO Board Representative for Neuropathology
| Joanna Phillips |
| USCF |
Available Credit
- 1.00 Attendance
Price
Cost:
$0.00
To register for this webinar, please follow these steps:
- If you have a Neuro-Oncology Academy account, select Login. If you do not yet have an account, select Register to create your FREE account. If you are a SNO member, select Login and on the next screen login under the “Society for Neuro-Oncology login.”
- Select Take Course. Answer the additional registration questions, then select Take Course.
We hope that this update makes the webinar viewing and credit claiming processes easier for you! Please don't hesitate to reach out to us at olivia@soc-neuro-onc.org with any questions.